Supplementation of arachidonic acid plus docosahexaenoic acid in cirrhotic patients awaiting liver transplantation: A preliminary study

Journal of Parenteral and Enteral Nutrition

Volumn 31, Issue 6, 2007, Pages 511-516

  Pazirandeh, Sassan ^b,d   Ling, Pei Ra ^a   Ollero, Mario ^a,e   Gordon, Fredric ^b   Burns, David L ^b   Bistrian, Bruce R ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ARACHIDONIC ACID; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; LINOLEIC ACID; LINOLENIC ACID; OLEIC ACID; PHOSPHOLIPID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR II; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FATTY ACID BLOOD LEVEL; FATTY ACID DESATURATION; HUMAN; LIPID BLOOD LEVEL; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NUTRITIONAL INTOLERANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

ALPHA-LINOLENIC ACID; ARACHIDONIC ACID; C-REACTIVE PROTEIN; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHOLIPIDS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35948949908     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607107031006511     Document Type: Article

References (18)

1. Gunnlaugsson O, Berkowitz D. Individual free fatty acids in patients with liver disease. Am J Dig Dis. 1977;22:1005-1009.
2. Wilcox HG, Dunn GD, Schenker S. Plasma long chain fatty acids and esterified lipids in cirrhosis and hepatic encephalopathy. Am J Med Sci. 1978;276:293-303.
3. Johnson SB, Gordon E, McClain C, Low G, Holman RT. Abnormal polyunsaturated fatty acid patterns of serum lipids in alcoholism and cirrhosis: arachidonic acid deficiency in cirrhosis. Proc Natl Acad Sci U S A. 1985;85:1815-1818.
4. Palombo JD, Lopes SM, Zeisel SH, et al. Abnormal polyunsaturated fatty acid patterns of serum lipids in alcoholism and cirrhosis: arachidonic acid deficiency in cirrhosis. Gastroenterology. 1987;93:1170-1171.
5. Duerksen DR, Nehra V, Palombo JD, Ahmad A, Bistrian BR. Essential fatty acid deficiencies in patients with chronic liver disease are not reversed by short-term intravenous lipid supplementation. Dig Dis Sci. 1999;44:1342-1348.
6. Rimola A, Gines P, Cuso E, et al. Prostaglandin precursor fatty acids in cirrhosis with ascites: effects of linoleic acid infusion in functional renal failure. Clin Sci. 1988;74:613-619.
7. Cabre E, Periago JL, Gonzalez J, et al. Plasma polyunsaturated fatty acids in liver cirrhosis with or without chronic hepatic encephalopathy: a preliminary study. JPEN J Parenter Enteral Nutr. 1992;16:359-363.
8. Cabre E, Abad-Lacruz A, Nunez MC, et al. The relationship of plasma polyunsaturated fatty acid deficiency with survival in advanced liver cirrhosis: multivariate analysis. Am J Gastroenterol. 1993;88:718-722.
9. Cabre E, Gassull MA. Polyunsaturated fatty acid deficiency in liver diseases: pathophysiological and clinical significance. Nutrition. 1996;12:542-548.
10. Miyamoto A, Wakabayashi H, Watanabe A. Abnormality in fatty acid composition of gastric mucosal phospholipids in patients with liver cirrhosis and its correction with polyunsaturated fatty acid-enriched soft oil capsule. J Gastroenterol Hepatol. 1997;12:644-652.
11. Bistrian BR. Clinical aspects of essential fatty acid metabolism: Jonathan Rhoads lecture. JPEN J Parenter Enteral Nutr. 2003;27:168-175.
12. Lehninger AL, ed. Biochemistry. 2nd ed. New York, NY: Worth Publishers, Inc; 1975:281, 669.
13. McDonald GB, Saunders DR, Weidman M, Fisher L. Portal venous transport of long-chain fatty acids absorbed from rat intestine. Am J Physiol. 1980;239:G141-G150.
14. Cabre E, Hernandez-Perez JM, Fluvia L, Pastor C, Corominas A, Gassull MA. Absorption and transport of dietary long-chain fatty acids in cirrhosis: a stable-isotope-tracing study. Am J Clin Nutr. 2005;81:692-701.
15. Nelson GJ, Kelley DS, Emken EA, Phinney SD, Kyle D, Ferretti A. A human dietary arachidonic acid supplementation study conducted in a metabolic research unit: rationale and design. Lipids. 1997;32:415-420.
16. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among U.S. men and women. Circulation. 2003;108:155-160.
17. Folch J, Lees M, Sloanestanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biochem. 1957;226:497-509.
18. Pantaleo P, Marra F, Vizzutti F, et al. Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. Clin Sci. 2004;106:27-34.